On-Treatment Elevation in Hepatic Transaminases during HCV Treatment with Ombitasvir, Paritaprevir, Dasabuvir, Ritonavir, and Ribavirin: A Case Series
Eradication of chronic hepatitis C virus (HCV) infection is now possible with all oral antiviral medications, including the combination of ombitasvir, paritaprevir, dasabuvir, and ritonavir (PrOD) with or without ribavirin. While high rates of sustained virologic response (SVR) can be achieved, a sm...
Saved in:
| Main Authors: | Madelyne Bean, Lydia Tang, Shyam Kottilil, Kimberly L. Beavers, Eric G. Meissner |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2016-01-01
|
| Series: | Case Reports in Infectious Diseases |
| Online Access: | http://dx.doi.org/10.1155/2016/6151570 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Real-life data on the efficacy and safety of ombitasvir/paritaprevir/ritonavir + dasabuvir +ribavirin in the patients with genotype 1 chronic hepatitis C virus infection in Serbia
by: Simonović-Babić Jasmina, et al.
Published: (2019-01-01) -
Drug Induced Pneumonitis Secondary to Treatment with Paritaprevir/Ritonavir/Ombitasvir and Dasabuvir (VIEKIRA PAK®) for Chronic Hepatitis C: Case Report of an Unexpected Life-Threatening Adverse Reaction
by: Shih Yea Sylvia Wu, et al.
Published: (2017-01-01) -
Clinico-laboratory and immunological characteristics of patients with compensated cirrhosis of the liver in the outcome of chronic hepatitis C on the background of treatment with a direct antiviral drug paritrapeprir/ritonavir/ombitasvir/ dasabuvir
by: L. L. Popova, et al.
Published: (2018-12-01) -
Elevation of transaminases. What if not the liver?
by: I. V. Sharkova
Published: (2024-04-01) -
Comparison of Therapeutic Response and Clinical Outcome between HCV Patients with Normal and Abnormal Alanine Transaminase Levels.
by: Cheng-Kung Wu, et al.
Published: (2016-01-01)